DAFNA Capital Management’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.11M | Buy |
627,626
+2,500
| +0.4% | +$20.4K | 1.41% | 19 |
|
|
2025
Q1 | $4.91M | Buy |
625,126
+370,909
| +146% | +$2.91M | 1.39% | 21 |
|
|
2024
Q4 | $3.79M | Sell |
254,217
-2,500
| -1% | -$37.2K | 0.96% | 27 |
|
|
2024
Q3 | $3.93M | Buy |
256,717
+3,500
| +1% | +$53.5K | 0.93% | 28 |
|
|
2024
Q2 | $3.86M | Buy |
253,217
+21,500
| +9% | +$327K | 0.92% | 31 |
|
|
2024
Q1 | $4.37M | Sell |
231,717
-1,000
| -0.4% | -$18.9K | 1% | 30 |
|
|
2023
Q4 | $4.44M | Buy |
232,717
+10,000
| +4% | +$191K | 1.07% | 31 |
|
|
2023
Q3 | $4M | Sell |
222,717
-3,000
| -1% | -$53.9K | 1.24% | 27 |
|
|
2023
Q2 | $4.58M | Buy |
225,717
+50,500
| +29% | +$1.03M | 1.25% | 26 |
|
|
2023
Q1 | $3.2M | Buy |
175,217
+33,000
| +23% | +$602K | 0.96% | 33 |
|
|
2022
Q4 | $2.94M | Sell |
142,217
-36,500
| -20% | -$755K | 0.83% | 36 |
|
|
2022
Q3 | $4.68M | Sell |
178,717
-9,000
| -5% | -$235K | 1.26% | 27 |
|
|
2022
Q2 | $4.76M | Buy |
187,717
+42,500
| +29% | +$1.08M | 1.3% | 24 |
|
|
2022
Q1 | $4.58M | Buy |
145,217
+28,017
| +24% | +$884K | 1.19% | 26 |
|
|
2021
Q4 | $4.74M | Sell |
117,200
-6,500
| -5% | -$263K | 1.19% | 23 |
|
|
2021
Q3 | $4.31M | Buy |
123,700
+4,000
| +3% | +$139K | 1.14% | 23 |
|
|
2021
Q2 | $3.29M | Buy |
119,700
+62,100
| +108% | +$1.71M | 0.69% | 37 |
|
|
2021
Q1 | $1.62M | Buy |
57,600
+8,000
| +16% | +$225K | 0.38% | 58 |
|
|
2020
Q4 | $1.29M | Sell |
49,600
-22,500
| -31% | -$584K | 0.38% | 55 |
|
|
2020
Q3 | $1.24M | Hold |
72,100
| – | – | 0.4% | 49 |
|
|
2020
Q2 | $1.78M | Buy |
72,100
+44,302
| +159% | +$1.1M | 0.51% | 42 |
|
|
2020
Q1 | $386K | Buy |
+27,798
| New | +$386K | 0.16% | 71 |
|
|
2018
Q2 | – | Sell |
-7,500
| Closed | -$116K | – | 80 |
|
|
2018
Q1 | $116K | Buy |
+7,500
| New | +$116K | 0.06% | 70 |
|